UPB Stock Summary and Trading Ideas (Upstream Bio | NASDAQ:UPB)

Upstream Bio Inc is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. It is developing verekitug, the known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin (TSLP), a cytokine that is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune-mediated diseases.

Upstream Bio trades on the NASDAQ stock market under the symbol UPB.

As of February 6, 2026, UPB stock price climbed to $26.20 with 510,252 million shares trading.

UPB has a beta of 0.85, meaning it tends to be less sensitive to market movements. UPB has a correlation of 0.04 to the broad based SPY ETF.

UPB has a market cap of $1.42 billion. This is considered a Small Cap stock.

Last quarter Upstream Bio reported $683,000 in Revenue and -$.63 earnings per share. This fell short of revenue expectation by $-11,080 and exceeded earnings estimates by $.15.

The top ETF exchange traded funds that UPB belongs to (by Net Assets): VTI, IWM, XBI, VXF, IWN.

UPB has outperformed the market in the last year with a return of +207.2%, while the SPY ETF gained +15.1%. In the last 3 month period, UPB beat the market returning +10.7%, while SPY returned +3.3%. However, in the most recent 2 weeks UPB has underperformed the stock market by returning -12.7%, while SPY returned +0.2%.

UPB support price is $24.72 and resistance is $27.28 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that UPB shares will trade within this expected range on the day.